Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS (2020) Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol 6:495. https://doi.org/10.1001/jamaoncol.2019.6143

Article  PubMed  PubMed Central  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–99. https://doi.org/10.1056/NEJMoa043330

Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331

Article  CAS  PubMed  Google Scholar 

Chamberlain MC (2010) Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10:1537–1544. https://doi.org/10.1586/ern.10.32

Article  CAS  PubMed  Google Scholar 

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncol 18:1199–1208. https://doi.org/10.1093/neuonc/now058

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verger A, Kas A, Darcourt J, Guedj E (2022) PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area. Cancers 14:1103. https://doi.org/10.3390/cancers14051103

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prather KY, O’Neal CM, Westrup AM, Tullos HJ, Hughes KL, Conner AK, Glenn CA, Battiste JD (2022) A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma. Neuro-Oncol Adv 4:vdac008. https://doi.org/10.1093/noajnl/vdac008

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chukwueke UN, Wen PY (2019) Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol 8:CNS28. https://doi.org/10.2217/cns-2018-0007

Ahrari S, Zaragori T, Zinsz A, Oster J, Imbert L, Verger A (2024) Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma. Sci Rep 14:3256. https://doi.org/10.1038/s41598-024-53693-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, Pellot-Barakat C, Soussan M, Frouin F, Buvat I (2018) LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res 78:4786–4789. https://doi.org/10.1158/0008-5472.CAN-18-0125

Article  CAS  PubMed  Google Scholar 

Zaragori T, Oster J, Roch V, Hossu G, Chawki MB, Grignon R, Pouget C, Gauchotte G, Rech F, Blonski M, Taillandier L, Imbert L, Verger A (2022) 18F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study. J Nucl Med Off Publ Soc Nucl Med 63:147–157. https://doi.org/10.2967/jnumed.120.261545

Article  CAS  Google Scholar 

Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougère C, Langen K-J, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn J-C, Weller M (2019) Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 46:540–557. https://doi.org/10.1007/s00259-018-4207-9

Article  CAS  PubMed  Google Scholar 

Albert NL, Galldiks N, Ellingson BM, Van Den Bent MJ, Chang SM, Cicone F, De Groot J, Koh E-S, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn J-C, Verger A, Weller M, Wen PY, Preusser M (2024) PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol 25:e29–e41. https://doi.org/10.1016/S1470-2045(23)00525-9

Article  PubMed  Google Scholar 

Bros M, Zaragori T, Rech F, Blonski M, Hossu G, Taillandier L, Marie P-Y, Verger A (2021) Effects of Carbidopa Premedication on 18F-FDOPA PET Imaging of Glioma: A Multiparametric Analysis. Cancers 13:5340. https://doi.org/10.3390/cancers13215340

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Pöpperl G, Kreth FW, la Fougere C, Weller M, Tonn JC, Network GG (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719. https://doi.org/10.1212/WNL.0000000000001262

Article  CAS  PubMed  Google Scholar 

Hirono S, Hasegawa Y, Sakaida T, Uchino Y, Hatano K, Iuchi T (2019) Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. Sci Rep 9:17794. https://doi.org/10.1038/s41598-019-54398-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rozenblum L, Zaragori T, Tran S, Morales-Martinez A, Taillandier L, Blonski M, Rech F, Galanaud D, Kas A, Verger A (2022) Differentiating high-grade glioma progression from treatment-related changes with dynamic [18F]FDOPA PET: a multicentric study. Eur Radiol 33:2548–2560. https://doi.org/10.1007/s00330-022-09221-4

Article  CAS  PubMed  Google Scholar